Added to YB: 2024-02-16
Pitch date: 2024-02-15
NVO [bullish]
Novo Nordisk A/S
-60.43%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 811.53
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
growth
Novo Nordisk: These Bold Moves Point Toward Upside
NONOF: Novo Nordisk a strong buy for 2024. Weight loss drug market to hit $100B by 2030, 15M US adults on meds. $8.3B investment to meet demand, cut costs. Wegovy reduces CV risk 20%. Double-digit sales & profit growth in 2023, optimistic 2024 outlook. Partnerships w/ Regeneron, Omega, Cellarity for innovative treatments. High valuation reflects strong growth expectations.
Read full article (8 min)